Yoon Hang Kim, MD, MPHBoard-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Abstract

Background. Endogenous opioid signaling and autonomic regulation share anatomy in the brainstem and converge clinically in conditions such as fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), hypermobile Ehlers-Danlos syndrome (hEDS), and Long COVID. Whether the endogenous opioid system contributes mechanistically to dysautonomia in these populations — and whether this relationship informs therapeutics such as low-dose naltrexone (LDN) — warrants a structured review.

Objective. To synthesize the mechanistic and clinical evidence linking endogenous opioidergic dysfunction to autonomic dysregulation, and to outline the therapeutic rationale for LDN in clients with the combined phenotype.

Key Findings. (1) μ- and δ-opioid receptors are densely expressed in the brainstem cardiovascular nuclei (NTS, RVLM, locus coeruleus); opioid tone normally restrains sympathetic outflow and supports baroreflex/vagal gain. (2) Modern PET imaging demonstrates reduced μ-opioid receptor availability in fibromyalgia, a more accurate framing than the older "endorphin deficiency" model based on inconsistent CSF peptide measurements. (3) Dysautonomia is highly prevalent across fibromyalgia, ME/CFS, Long COVID (≈66% with moderate-to-severe autonomic dysfunction), and the POTS/MCAS/hEDS triad, with substantial phenotypic overlap. (4) LDN acts through two complementary mechanisms — transient μ-opioid receptor blockade triggering endogenous opioid upregulation, and TLR4-mediated suppression of microglial neuroinflammation — and has demonstrated efficacy in fibromyalgia (pooled SMD −0.85 for pain) with emerging evidence in Long COVID.

Conclusion. Endogenous opioidergic dysfunction is a mechanistically coherent and clinically useful lens for understanding overlapping pain-fatigue-dysautonomia phenotypes. LDN offers a low-cost, well-tolerated intervention that targets both opioidergic tone and neuroinflammation, and deserves consideration early in the clinical course for appropriately selected clients.

Keywords: endogenous opioids; β-endorphin; μ-opioid receptor; dysautonomia; POTS; fibromyalgia; ME/CFS; Long COVID; MCAS; low-dose naltrexone; LDN; neuroinflammation.

The Question Behind the Question

When a client presents with the now-familiar constellation of widespread pain, fatigue, orthostatic intolerance, brain fog, and gut symptoms, two physiological systems consistently show fingerprints on the case: the endogenous opioid system and the autonomic nervous system. These two systems are not parallel tracks — they share anatomy, share regulators, and share a common vulnerability to chronic stress, infection, and inflammation. Understanding the link helps explain why so many of these clients carry overlapping diagnoses (fibromyalgia, POTS, ME/CFS, MCAS, Long COVID, hypermobility spectrum disorders) and why a single intervention, low-dose naltrexone (LDN), can produce broad benefit in this population.

This article walks through the mechanistic basis, the clinical evidence in each major condition, and how LDN fits into the picture — along with the caveats that matter at the bedside.

How the Endogenous Opioid System Regulates Autonomic Function

Brainstem Cardiovascular Control

The brainstem nuclei that govern moment-to-moment cardiovascular function — the nucleus tractus solitarius (NTS), the rostral ventrolateral medulla (RVLM), the nucleus ambiguus, and the locus coeruleus — are densely populated with μ- and δ-opioid receptors. Microinjection of opioid agonists into the NTS modulates baroreflex-mediated cardiovascular responses [1], and systemic μ-opioid stimulation in humans measurably reduces muscle sympathetic nerve activity [2]. In other words, endogenous opioid tone normally acts as a brake on sympathetic outflow and helps preserve vagal/baroreflex gain.

When this opioidergic restraint weakens — whether from receptor downregulation, ligand depletion, or microglial-driven receptor desensitization — the system tilts toward sympathetic overdrive, reduced heart rate variability (HRV), and blunted baroreflex sensitivity. These are the physiologic signatures clinicians recognize as dysautonomia.

HPA Axis and Sympathoadrenal Modulation

β-endorphin is co-secreted with ACTH from the cleavage of pro-opiomelanocortin (POMC) during HPA activation [3]. Arcuate β-endorphin neurons provide direct inhibitory input to hypothalamic CRH neurons and indirectly restrain CRH-stimulatory locus coeruleus noradrenergic output [4]. The endogenous opioid system thus serves as a built-in negative-feedback dampener on the stress response — both the neuroendocrine arm (HPA) and the autonomic arm (sympathoadrenal). When this dampener fails, stress responses become disproportionate and prolonged.

Peripheral Autonomic Effects

Opioid receptors are expressed on autonomic ganglia, enteric neurons, sweat glands, bladder smooth muscle, and vascular endothelium. Endogenous opioid tone therefore shapes downstream autonomic output well beyond central control — affecting gut motility, secretomotor function, and vascular reactivity. This helps explain why dysautonomia tends to be multi-system rather than confined to the cardiovascular compartment.

Evidence for Endogenous Opioid System Dysfunction in Chronic Pain Syndromes

An important nuance: early cerebrospinal fluid (CSF) studies in fibromyalgia did not show low β-endorphin levels — CSF β-endorphin was normal compared with controls [5], and CSF enkephalins were actually elevated [6]. For years this was taken as evidence against an endorphin-deficiency model. Modern neuroimaging, however, has revised the picture.

Using positron emission tomography (PET) with the μ-opioid receptor (MOR) selective ligand [11C]-carfentanil, Harris and colleagues demonstrated reduced μ-opioid receptor availability in several pain-processing brain regions in opioid-naïve fibromyalgia patients compared with healthy controls [7]. A subsequent study by the same group correlated this reduced MOR availability with diminished pain-evoked neural activity in antinociceptive regions including the dorsolateral prefrontal cortex and anterior cingulate cortex [8]. The contemporary interpretation: the problem is not necessarily a lack of endogenous ligand, but rather a dysfunctional opioidergic system — reduced receptor availability, altered receptor sensitivity, and impaired downstream signaling. This dysfunction reduces descending pain inhibition and, by extension, the opioidergic brake on sympathetic outflow.

Where Opioidergic Dysfunction and Dysautonomia Converge Clinically

Fibromyalgia and POTS

Postural orthostatic tachycardia syndrome (POTS) and fibromyalgia frequently co-occur. The American College of Cardiology JACC Focus Seminar on POTS lists fibromyalgia as a major comorbidity, and notes that chronic fatigue, fibromyalgia, joint hypermobility, migraine, and functional GI disorders cluster together in POTS independently of strict hemodynamic criteria [9]. A 2026 case-control study of 305 patients found central sensitization syndrome in 86.5% of POTS patients — a striking overlap with fibromyalgia phenotypes [10]. The shared phenotype suggests shared mechanism, and reduced central opioidergic tone is one of the few candidates that explains both the pain amplification and the autonomic dysregulation.

ME/CFS and Autonomic Dysfunction

Heart rate variability (HRV) studies in ME/CFS consistently demonstrate reduced parasympathetic indices and elevated low-frequency/high-frequency ratios, indicating sympathovagal imbalance [11]. A systematic review and meta-analysis confirmed elevated resting heart rate, exaggerated tilt-table HR response, and reduced high-frequency HRV in ME/CFS compared with controls [12]. Many of these clients carry comorbid POTS, and the pattern of autonomic dysregulation persists even during sleep, suggesting a sustained tonic perturbation rather than a state effect.

Long COVID / Post-Acute Sequelae of SARS-CoV-2 (PASC)

Autonomic dysfunction is now considered a defining feature of Long COVID. A global survey of 2,314 adults with PASC found moderate-to-severe autonomic dysfunction in 66% of respondents, independent of acute illness severity [13]. A cross-sectional study of 320 post-COVID patients using the COMPASS-31 instrument found high prevalence of orthostatic intolerance, secretomotor dysfunction, and GI symptoms [14]. Prospective autonomic testing studies have confirmed objective dysautonomia and POTS in a substantial subset [15]. Notably, Long COVID shares clinical and mechanistic features with ME/CFS, and shares the same therapeutic responsiveness to LDN in early clinical reports.

Mast Cell Activation Syndrome, hEDS, and the Triad

The clinical triad of POTS, MCAS, and hypermobile Ehlers-Danlos syndrome (hEDS) is well described. Hyperadrenergic POTS in mast cell activation disorders was characterized by Shibao and colleagues in 2005, with elevated norepinephrine, episodic flushing, and tachycardia [16]. Subsequent work has shown a high prevalence of MCAS in hEDS/POTS cohorts, and mast cell mediators — histamine, tryptase, prostaglandin D2 — directly perturb autonomic tone through vascular reactivity, norepinephrine release, and small-fiber neural irritation [17, 18]. Mast cell proteases can also degrade neuropeptides, which has been hypothesized to contribute to a relative endogenous opioid insufficiency in chronically activated MCAS clients — though this specific mechanism remains to be fully validated.

The LDN Bridge: Mechanism and Clinical Relevance

Low-dose naltrexone (LDN, typically 0.5–4.5 mg nightly) is a uniquely positioned intervention because it acts on both arms of the opioid-dysautonomia link. Two mechanisms are most relevant [19, 20]:

• Endogenous opioid upregulation. Transient μ-opioid receptor blockade (4–6 hours from a short LDN half-life) triggers compensatory upregulation of endogenous opioid production and receptor sensitivity. The net effect over 18–24 hours is increased opioidergic tone — the opposite of what a steady-state full naltrexone dose would produce.
• Microglial / TLR4 modulation. Naltrexone at low doses antagonizes toll-like receptor 4 (TLR4) on microglia, reducing pro-inflammatory cytokine release. Since neuroinflammation contributes to both central sensitization and autonomic dysregulation, this anti-inflammatory effect compounds the opioidergic benefit.

Clinically, this maps onto the observation that LDN responders frequently carry the combined phenotype: fibromyalgia + POTS, MCAS + dysautonomia, Long COVID with orthostatic intolerance, ME/CFS with HRV impairment. A 2024 systematic review and meta-analysis of randomized trials in fibromyalgia found significant reductions in pain (pooled SMD −0.85) and improvement in function on the FIQR [21]. Observational and small interventional studies in Long COVID have shown improvement in fatigue, pain, sleep, and cognition over 2–6 months [22, 23].

Important Caveats

Several points warrant emphasis at the bedside:

• LDN evidence is still emerging. While the mechanistic rationale is robust and clinical experience is favorable, the randomized trial base in dysautonomia specifically is small. Most current evidence is in fibromyalgia, with extrapolation to dysautonomia-predominant phenotypes.
• Titration matters. Too-rapid escalation can transiently worsen symptoms — including dysautonomic ones — before the rebound upregulation establishes itself. The clinical correlate of the so-called "LDN sweet spot" is finding the dose at which opioidergic upregulation is maximized without inducing transient depletion or sleep disruption.
• Not every dysautonomia is opioidergic. Volume depletion, deconditioning, structural neuropathy, medication side effects, hyperadrenergic POTS driven by clear adrenergic autoantibodies, and pheochromocytoma must all be considered. LDN is not a substitute for thoughtful diagnostic workup.
• Concomitant opioid use. LDN is contraindicated for clients taking opioid analgesics or partial agonists. Co-administration can precipitate withdrawal or block opioid analgesia.

Clinical Implications

For clinicians who care for clients with overlapping pain-fatigue-dysautonomia phenotypes, the endogenous opioid system deserves a seat at the differential diagnostic table — not as a discrete diagnosis, but as a mechanistic lens that helps unify what otherwise looks like a confusing constellation. Practical takeaways:

• Screen for autonomic symptoms (COMPASS-31, orthostatic vitals, 10-minute stand test) in every client with chronic pain or fatigue.
• Screen for chronic pain, fatigue, and central sensitization in every client presenting with dysautonomia.
• Consider LDN early in clients who exhibit the combined phenotype, particularly those with post-infectious onset (Long COVID, post-viral ME/CFS) where neuroinflammation is plausible.
• Titrate slowly. Start at 0.5–1.0 mg nightly and adjust based on response and tolerability over weeks, not days.
• Address comorbid drivers in parallel: volume status, mast cell activation, micronutrient deficiencies, sleep quality, and exercise tolerance (with pacing for ME/CFS to avoid post-exertional malaise).

The endogenous opioid system is not a fringe target. It sits at the crossroads of pain, mood, stress, immunity, and autonomic regulation — and when it falters, the consequences ripple across all of those domains. Recognizing this convergence is what allows integrative medicine to do what it does best: treat the system, not just the symptom.

Conclusion

The convergence of endogenous opioidergic dysfunction and autonomic dysregulation is not a theoretical curiosity — it is the unifying thread that runs through some of the most challenging clients in integrative practice. Fibromyalgia, ME/CFS, POTS, MCAS, hEDS, and Long COVID are still cataloged in the medical literature as distinct entities with distinct specialists. At the bedside, they cluster. They share post-infectious or post-stress triggers, they share central sensitization, they share reduced HRV, they share orthostatic intolerance, and — as the imaging and pharmacologic data now suggest — they likely share a common dysfunction in the opioidergic-autonomic interface.

Three points deserve to be carried forward into clinical practice:

• Look for the combined phenotype. A client with widespread pain or post-exertional fatigue should be evaluated for orthostatic intolerance; a client with POTS or unexplained tachycardia should be evaluated for central sensitization and fatigue. The screening tools are inexpensive (COMPASS-31, 10-minute stand test, Widespread Pain Index). Most of these clients have been seen by multiple specialists and still left unrecognized as a single phenotype.
• Treat the mechanism, not the label. Whether the chart reads "fibromyalgia" or "Long COVID" or "hyperadrenergic POTS," the underlying opioidergic-neuroinflammatory axis may be the same. LDN is one of the few interventions that addresses both arms of this axis with a favorable safety profile and low cost. It is rarely curative, but it is frequently disease-modifying enough to make the rest of integrative care — sleep restoration, paced reconditioning, mast cell stabilization, nutritional repletion — feasible where it previously was not.
• Stay humble about what we don't know. The mechanistic story is coherent, but the randomized trial base in dysautonomia specifically remains thin. The clinician's role is to apply what is known carefully, to titrate based on the individual client's response, and to keep watching the literature as larger trials in Long COVID, POTS, and ME/CFS read out over the next few years.

Integrative medicine has always argued that the body is a system, not a collection of organ-system silos. The endorphin-dysautonomia link is, in many ways, a vindication of that view. It is a reminder that the most useful clinical insights often emerge not from a single specialty's deepest dive, but from the willingness to look across the boundaries where two systems meet.

References

1. Hassen AH, Feuerstein G. μ-Opioid receptors in NTS elicit pressor responses via sympathetic pathways. Am J Physiol. 1987;252(1 Pt 2):H156-H162.

2. Kienbaum P, Heuter T, Pavlakovic G, Michel MC, Peters J. Chronic μ-opioid receptor stimulation in humans decreases muscle sympathetic nerve activity. Circulation. 2001;103(6):850-855.

3. Molina PE. Opioids and opiates: analgesia with cardiovascular, haemodynamic and immune implications in critical illness. J Intern Med. 2006;259(2):138-154.

4. Valentino RJ, Van Bockstaele E. Endogenous opioids: the downside of opposing stress. Neurobiol Stress. 2015;1:23-32.

5. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Cerebrospinal fluid levels of beta-endorphin in patients with fibromyalgia (fibrositis syndrome). J Rheumatol. 1988;15(12):1804-1806.

6. Baraniuk JN, Whalen G, Cunningham J, Clauw DJ. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord. 2004;5:48.

7. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27(37):10000-10006.

8. Schrepf A, Harper DE, Harte SE, et al. Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study. Pain. 2016;157(10):2217-2225.

9. Bryarly M, Phillips LT, Fu Q, Vernino S, Levine BD. Postural Orthostatic Tachycardia Syndrome: JACC Focus Seminar. J Am Coll Cardiol. 2019;73(10):1207-1228.

10. Mathew GT, Novak P. Prevalence of central sensitization in postural tachycardia syndrome. JAMA Netw Open. 2026;9(1):e2553694.

11. Escorihuela RM, Capdevila L, Castro JR, et al. Reduced heart rate variability predicts fatigue severity in individuals with chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med. 2020;18(1):4.

12. Nelson MJ, Bahl JS, Buckley JD, Thomson RL, Davison K. Evidence of altered cardiac autonomic regulation in myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(43):e17600.

13. Larsen NW, Stiles LE, Shaik R, et al. Characterization of autonomic symptom burden in long COVID: a global survey of 2,314 adults. Front Neurol. 2022;13:1012668.

14. Eldokla AM, Mohamed-Hussein AA, Fouad AM, et al. Prevalence and patterns of symptoms of dysautonomia in patients with long-COVID syndrome: a cross-sectional study. Ann Clin Transl Neurol. 2022;9(6):778-785.

15. Seeley MC, Gallagher C, Ong E, et al. High incidence of autonomic dysfunction and postural orthostatic tachycardia syndrome in patients with long COVID: implications for management and health care planning. Am J Med. 2023;136(6):568-574.

16. Shibao C, Arzubiaga C, Roberts LJ 2nd, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45(3):385-390.

17. Kohn A, Chang C. The relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS). Clin Rev Allergy Immunol. 2020;58(3):273-297.

18. Theoharides TC, Tsilioni I, Bawazeer M. Mast cells, neuroinflammation and pain in fibromyalgia syndrome. Front Cell Neurosci. 2019;13:353.

19. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459.

20. Toljan K, Vrooman B. Low-dose naltrexone (LDN) — review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82.

21. Yang J, et al. Efficacy and safety of low-dose naltrexone for the treatment of fibromyalgia: a systematic review and meta-analysis. Presented at ACR Convergence 2025. Arthritis Rheumatol. 2025;77(Suppl).

22. O'Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long COVID cohort: an interventional pre-post study. Brain Behav Immun Health. 2022;24:100485.

23. Bonilla H, Tian L, Marconi VC, et al. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. Int Immunopharmacol. 2023;124(Pt B):110966.

About Dr. Kim

Yoon Hang Kim, MD, MPH is a board-certified Preventive Medicine physician with more than 20 years of clinical experience in integrative and functional medicine. He completed a fellowship at the University of Arizona Andrew Weil Center for Integrative Medicine under the mentorship of Dr. Andrew Weil and is certified in medical acupuncture through UCLA. He holds additional certifications in preventive medicine, integrative medicine, holistic medicine, and functional medicine.

Dr. Kim specializes in low-dose naltrexone (LDN) therapy, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome (ME/CFS), mast cell activation syndrome (MCAS), and mold-related illness. He is the author of three books and more than 20 peer-reviewed articles, with a focus on LDN therapy and integrative approaches to complex chronic illness.

Professional: www.yoonhangkim.com    |   

Clinical: www.directintegrativecare.com